Literature DB >> 9208188

Myeloperoxidase and interleukin-8 levels in chronic sinusitis.

P Demoly1, L Crampette, M Mondain, I Enander, I Jones, J Bousquet.   

Abstract

We have recently phenotyped inflammation in non-infectious allergic and non-allergic chronic maxillary sinusitis using sinus biopsies and lavage fluids. In this first paper, we have concentrated our work on the eosinophil, T cell, mast cell and macrophage infiltrates. However, many unresolved questions remain and particularly the role of neutrophils needed to be addressed. In the present study, we focused on the neutrophilic inflammation: myeloperoxidase (MPO) and interleukin-8 (IL-8) were measured by immunoassays and neutrophils were enumerated by conventional staining in the sinus lavage fluids of 16 patients with chronic sinusitis and six control subjects. Both MPO and IL-8 levels were significantly higher in patients than in controls (P < 0.01 and 0.005, respectively). There was a significant correlation between MPO levels and neutrophil numbers, and between MPO and IL-8 levels in the sinus lavage fluid (P < 0.0001, Spearman rank correlation). The presence of high levels of IL-8 in the lavage fluids of patients suffering from chronic sinusitis, levels which correlate with those of MPO, suggests that this cytokine may activate neutrophils in this chronic disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208188

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

1.  Myeloperoxydase expression in the pathogenesis of nasal polyps.

Authors:  Burcin A Sarisoy; Mehmet Eken; Alev Z Oktay; Mustafa Paksoy; Arif Sanli
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-04-13

Review 2.  Rhinosinusitis: Establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  Otolaryngol Head Neck Surg       Date:  2004-12       Impact factor: 3.497

Review 3.  Rhinosinusitis: establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  J Allergy Clin Immunol       Date:  2004-12       Impact factor: 10.793

4.  [Primary nasal epithelial cells and fibroblasts have inflammation-inducing functions].

Authors:  C Rudack; W Stoll; W Hermann
Journal:  HNO       Date:  2003-04-08       Impact factor: 1.284

Review 5.  The role of infection in chronic rhinosinusitis.

Authors:  Neil Bhattacharyya
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

6.  Drug management in chronic rhinosinusitis: identification of the needs.

Authors:  Jean-Baptiste Hpj Watelet; Philippe H Eloy; Paul B van Cauwenberge
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

Review 7.  Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives.

Authors:  Amjad A Khan; Mohammed A Alsahli; Arshad H Rahmani
Journal:  Med Sci (Basel)       Date:  2018-04-18

Review 8.  Molecular immunology and immunotherapy for chronic sinusitis.

Authors:  Lily H P Nguyen; Samer Fakhri; Saul Frenkiel; Qutayba A Hamid
Journal:  Curr Allergy Asthma Rep       Date:  2003-11       Impact factor: 4.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.